2022 Updates: Part 1 – Understanding the Changing Treatment Landscape of Chronic Rhinosinusitis with Nasal Polyps

Released On
November 17, 2021

Expires On
November 16, 2022

Media Type

Completion Time
60 minutes

Allergy & Immunology, Primary Care


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Horizon CME.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.0 Contact Hour(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of physicians and other clinicians who treat patients with chronic rhinosinusitis with nasal polyps, including specialists (allergists, immunologists, ENTs) and other health care providers who may treat CRSwNP patients.

Program Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic condition that negatively impacts patients’ quality of life and while CRSwNP pathogenesis is poorly understood, type 2 inflammation has been identified as a major driver for most CRSwNP pathophysiology. Increased understanding has resulted in a new class of medical therapy and targeted biologics to address existing unmet medical needs. As such, it is important for clinicians to understand the rationale behind these new treatments and how best to integrate targeted therapies with existing treatment options.

In this roundtable discussion, expert faculty in CRSwNP offer valuable discussions regarding treatment indications, efficacy, and side effects. Improving learners’ knowledge of type 2 inflammation and immunomodulating therapies as well as improving their competence relating to selection of interventions, individualizing CRSwNP treatments, and optimizing patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify how type 2 inflammation contributes to the pathology of chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Describe the role of immunomodulation for treatment of chronic rhinosinusitis with nasal polyps
  • Assess the role of medications and surgery for the treatments of CRSwNP
  • Individualize CRSwNP treatment based on patient needs and preferences


Stella E. Lee, MD (Moderator)

Section Chief, Rhinology at Brigham and Women's Hospital
Boston, Massachusetts


Eileen Wang, MD, MPH

Assistant Professor Division of Allergy & Clinical Immunology Department of Medicine
National Jewish Health
Denver, CO

Joseph K. Han, MD, FARS, FAAOA

Medical Director, Division of Allergy, Eastern Virginia Medical School
Division of Rhinology & Endoscopic Sinus and Skull Base Surgery

Physician Accreditation Statement

Horizon CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

Horizon CME designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nurses Accreditation Statement

The Nurse Practitioner Healthcare Foundation (NPHF) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria.

Nurses Credit Designation

This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Awarded: 1.0 contact hour(s)

Disclosures of Conflicts of Interest


  • Dr Joseh Han has served as a consultant for Sanofi, AstraZeneca, GSK, and Genentech during the past 24 months.*
  • Dr Stella Lee has served on Advisory Boards, as a Consultant, and recevied research support from AstraZeneca, Genentech, GSK, and Sanofi Regeneron during the past 24 months.*
  • Dr Eileen Wang has served on Speakers Bureaus for AstraZeneca, on Advisory Boards for AstraZeneca and GlaxoSmithKline, as a Consultant for WeFight and Clinical Care Options, and received Research Support from AstraZeneca, GlaxoSmithKline, Genentech, Sema4, Sanofi, and Optimum Patient Care Ltd during the past 24 months.*

*Horizon CME has mitigated and resolved all relevant financial relationships


Those involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test.
  4. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: info@horizoncme.com

Copyright Information

Copyright © 2021 by Horizon CME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.